KRAS and neoplasm: In contrast to the findings of a previous study in which STK11 and KEAP1 mutation carriers exhibited decreased tumor proportion scores (TPSs) for PD-L1 expression [25], we only observed that STK11-mutant patients and STK11-mutant but KRAS wild-type patients might be less likely to exhibit PD-L1 positivity.